Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma Journal Article
| Authors: | Zurko, J.; Ramdial, J.; Shadman, M.; Ahmed, S.; Szabo, A.; Iovino, L.; Tomas, A. A.; Sauter, C.; Perales, M. A.; Shah, N. N.; Acharya, U. H.; Jacobson, C.; Soiffer, R. J.; Wang, T.; Komanduri, K. V.; Jaglowski, S.; Kittai, A. S.; Denlinger, N.; Iqbal, M.; Kharfan-Dabaja, M. A.; Ayala, E.; Chavez, J.; Jain, M.; Locke, F. L.; Samara, Y.; Budde, L. E.; Mei, M. G.; Della Pia, A.; Feldman, T.; Ahmed, N.; Jacobs, R.; Ghosh, N.; Dholaria, B.; Oluwole, O. O.; Hess, B.; Hassan, A.; Kenkre, V. P.; Reagan, P.; Awan, F.; Nieto, Y.; Hamadani, M.; Herrera, A. F. |
| Article Title: | Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma |
| Abstract: | Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients ex-periencing treatment failure after chimeric antigen receptor T-cell therapy (CAR T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT in LBCL patients following CAR T failure. Eighty-eight patients with relapsed, refractory LBCL received an alloHCT following anti-CD19 CAR T failure. The median number of lines of therapy between CAR T infusion and alloHCT was one (range, 0-7). Low intensity conditioning was used in 77% (n=68) and peripheral blood was the most common graft source (86%, n=76). The most common donor types were matched unrelated donor (39%), followed by ha-ploidentical (30%) and matched related donor (26%). Median follow-up of survivors was 15 months (range, 1-72). One-year overall survival, progression-free survival, and graft -versus-host disease-free relapse-free survival were 59%, 45%, and 39% respectively. One-year non-relapse mortality and progression/relapse were 22% and 33% respectively. On multivariate analy-sis, <2 lines of intervening therapy between CAR T and alloHCT and complete response at time of alloHCT were associated with better outcomes. In conclusion, alloHCT after CAR T failure can provide durable remissions in a subset of patients. |
| Keywords: | diagnosis; management; multicenter; chronic leukemia; single-arm |
| Journal Title: | Haematologica |
| Volume: | 108 |
| Issue: | 1 |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2023-01-01 |
| Start Page: | 98 |
| End Page: | 109 |
| Language: | English |
| ACCESSION: | WOS:001003620300007 |
| DOI: | 10.3324/haematol.2022.281242 |
| PROVIDER: | wos |
| PMCID: | PMC9827150 |
| PUBMED: | 35833303 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work